Janssen Scoops Up XO1

No, XO1 is not a drug candidate, it’s the name of an asset-centric virtual biopharmaceutical company, XO1 Limited, a UK-based portfolio company of Index Ventures. Janssen Pharmaceuticals (NYSE: JNJ) paid an undisclosed price for the virtual company, which was founded solely to develop the anti-thrombin antibody ichorcumab, which basically acts as an anticoagulant but doesn’t cause bleeding, like previous blood thinners. XO1 and Index Ventures licensed the technology from Cambridge University Hospitals, where it was developed. Read More »